This trial is evaluating whether STMC-103H will improve 3 primary outcomes, 12 secondary outcomes, and 1 other outcome in patients with Dermatitis. Measurement will happen over the course of Through 56 days of study.
This trial requires 264 total participants across 6 different treatment groups
This trial involves 6 different treatments. STMC-103H is the primary treatment being studied. Participants will be divided into 3 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Participation is compensated
You will be compensated for participating in this trial.
"Symptoms of hypersensitivity include a feeling of coldness, headache, and muscle weakness. Other, less common symptoms include hives and swelling of the face, lips, tongue, throat, ears, or throat and neck. These symptoms usually precede a rash with itching sensations.\n" - Anonymous Online Contributor
"The treatment of hypersensitivity is less radical, and thus less successful. It may be that we are still studying the right method and administering the method in a more effective way. With respect to the treatment of hypersensitivity, the current study suggests, first, that clinicians can manage hypersensitivity better if they understand the underlying mechanisms, are aware of their own biases, and choose to use the most appropriate method for the given situation." - Anonymous Online Contributor
"We recommend to try the drugs recommended by the European College of Allergy and Immunology instead of the drugs recommended by the American College of Allergy, Asthma, and Immunology. It is essential to be aware about the dangers of all these drugs during the application. And when considering the patients it is important to understand the possible combinations of the drugs which could result in new side effects. Other drugs like NSAIDs and statins should be prescribed cautiously in the elderly and women taking oral contraception." - Anonymous Online Contributor
"A few patients in every hundred get HSP annually. The great majority, however, get the disease infrequently. The frequency of occurrence of HSP is thought to depend on both the frequency of the antigen and the amount of antigen in the environment." - Anonymous Online Contributor
"The study showed that patients with SJS and AGEP are prone to developing hypersensitivity hypersensitivity. They are also at risk for developing adverse effects related to medications related to allergic reaction such as ACE inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs, corticosteroids, and immunosuppressants. Physicians and patients should be informed of the potential for allergies and hypersensitive reactions. Further research regarding the relationship between allergy and hypersensitivity needs to be investigated." - Anonymous Online Contributor
"Immune hypersensitivity reactions are believed to be one cause of allergic bronchopulmonary aspergillosis and hypersensitivity pneumonitis. Allergy to mold, insects and some environmental irritants causes allergic bronchopulmonary aspergillosis. In contrast, inhalant hypersensitivity to metals, silicates, food additives and pesticides leads to hypersensitivity pneumonitis. The hypersensitive reaction in idiopathic pulmonary fibrosis most commonly occurs to inhaled silicates. The hypersensitive reaction also occurs in the setting of systemic immunosuppression, such as in recipients of cytotoxic drugs." - Anonymous Online Contributor
"The present results should be useful to all investigators conducting clinical trials of the stmc-103h molecule, as it may help determine the utility of such stmc-103h molecule in treatment of various disease indications in comparison with currently used anticancer drugs, which are mainly based on cytotoxic effects or immunosuppressive effects." - Anonymous Online Contributor
"Stmc-103h (5 x 1 g oral, once daily for 7 days) improved QoL in a cohort of patients with hypersensitivity to both steroids and antibiotics. In a phase 3 multicenter, randomized trial, in which patients will be randomized to treatment or placebo, Stmc-103h is being evaluated as a treatment for patients with systemic hypersensitivity reactions to both steroids and antibiotics." - Anonymous Online Contributor
"The data indicate that stmc-103h exerts its therapeutic effects through modulation of innate and adaptive immune responses that are mediated chiefly through the suppression of pro-inflammatory IL-12p70 and the consequential reduction in the activation of IFN-γ-producing T-cells." - Anonymous Online Contributor
"Most hypersensitizants tested are extremely dangerous, producing death by acute asthma or other allergic reactions in severe cases. For those with moderate reactions, life-threatening asthma could also occur." - Anonymous Online Contributor
"In addition, the stmc-103h has been used as the sole treatment in combination with other conventional treatments (2/4 trials) and in combination with interferon (1 trial). Due to the preliminary nature of these studies, conclusions on the use of stmc-103h alone or in combination with other treatments cannot be made." - Anonymous Online Contributor
"Stmc-103h has a broad in vitro antiinflammatory activity that has demonstrated efficacy in phase II clinical trials when given subcutaneously or intravenously to patients with rheumatoid arthritis." - Anonymous Online Contributor